1480 related articles for article (PubMed ID: 21375482)
1. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
2. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.
Prediger RD; Aguiar AS; Rojas-Mayorquin AE; Figueiredo CP; Matheus FC; Ginestet L; Chevarin C; Bel ED; Mongeau R; Hamon M; Lanfumey L; Raisman-Vozari R
Neurotox Res; 2010 Feb; 17(2):114-29. PubMed ID: 19629612
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Matheus FC; Aguiar AS; Castro AA; Villarinho JG; Ferreira J; Figueiredo CP; Walz R; Santos AR; Tasca CI; Prediger RD
Behav Brain Res; 2012 Dec; 235(2):263-72. PubMed ID: 22921927
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
[TBL] [Abstract][Full Text] [Related]
5. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
[TBL] [Abstract][Full Text] [Related]
6. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
Castro AA; Ghisoni K; Latini A; Quevedo J; Tasca CI; Prediger RD
Behav Brain Res; 2012 Apr; 229(1):208-15. PubMed ID: 22266923
[TBL] [Abstract][Full Text] [Related]
7. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
9. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
Prediger RD
J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
[TBL] [Abstract][Full Text] [Related]
10. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
11. MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
Fujita A; Fujita Y; Pu Y; Chang L; Hashimoto K
Psychopharmacology (Berl); 2020 Jan; 237(1):83-92. PubMed ID: 31418048
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.
Tristão FS; Amar M; Latrous I; Del-Bel EA; Prediger RD; Raisman-Vozari R
Neurotox Res; 2014 Jan; 25(1):24-32. PubMed ID: 23690159
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
[TBL] [Abstract][Full Text] [Related]
14. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
[TBL] [Abstract][Full Text] [Related]
15. Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade.
Kuo HC; Lu CC; Shen CH; Tung SY; Hsieh MC; Lee KC; Lee LY; Chen CC; Teng CC; Huang WS; Chen TC; Lee KF
J Transl Med; 2016 Mar; 14():78. PubMed ID: 26988860
[TBL] [Abstract][Full Text] [Related]
16. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.
Hsieh MH; Gu SL; Ho SC; Pawlak CR; Lin CL; Ho YJ; Lai TJ; Wu FY
Behav Brain Res; 2012 Apr; 229(1):41-7. PubMed ID: 22227506
[TBL] [Abstract][Full Text] [Related]
17. Neurochemical findings in the MPTP model of Parkinson's disease.
Schmidt N; Ferger B
J Neural Transm (Vienna); 2001; 108(11):1263-82. PubMed ID: 11768626
[TBL] [Abstract][Full Text] [Related]
18. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
[TBL] [Abstract][Full Text] [Related]
19. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
[TBL] [Abstract][Full Text] [Related]
20. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
